Email RIS file
Bookmark
Report an Issue

Anticancer drug development / edited by Bruce C. Baguley, David J. Kerr

Published
San Diego : Academic Press, [2002]
Copyright Date
©2002
Physical Description
xiii, 397 pages : illustrations (some color) ; 29 cm
Additional Creators
Baguley, Bruce C. and Kerr, David J.

Availability

I Want It
I Want It

Finding items...

Contents
A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic principle -- Tumor imaging applications in the testing of new drugs -- Mechanistic approaches to Phase I clinical trials.
Subject(s)
ISBN
0120726513 (alk. paper)
Bibliography Note
Includes bibliographical references and index.
View MARC record | catkey: 2320561